A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis

Applied Health Economics and Health Policy

Volumn 13, Issue 5, 2015, Pages 469-483

  de Graaff, Barbara ^a   Neil, Amanda ^a   Sanderson, Kristy ^a   Si, Lei ^a   Yee, Kwang Chien ^b   Palmer, Andrew J ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROPATHY; AUTOSOMAL RECESSIVE DISORDER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FATIGUE; HEALTH CARE COST; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HUMAN; LETHARGY; PENETRANCE; PROGRAM EFFECTIVENESS; REVIEW; SCREENING; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; VEIN PUNCTURE; COST BENEFIT ANALYSIS; ECONOMICS; ETHICS; MASS SCREENING;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEMOCHROMATOSIS; HUMANS; MASS SCREENING;

EID: 84942371059     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-015-0189-y     Document Type: Review

References (107)

1. Worwood M. Inborn errors of metabolism: iron. Br Med Bull. 1999;55(3):556–67.
2. Allen K. Hereditary haemochromatosis—diagnosis and management. Aust Fam Physician. 2010;39(12):938–41.
3. Wood MJ, Skoien R, Powell LW. The global burden of iron overload. Hepatol Int. 2009;3(3):434–44.
4. Feder JN. The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis. Immunol Res. 1999;20(2):175–85.
5. Altes A, et al. Prevalence of the C282Y, H63D, and S65C mutations of the HFE gene in 1,146 newborns from a region of Northern Spain. Genet Test. 2004;8(4):407–10.
6. Pedersen P, Melsen GV, Milman N. Frequencies of the haemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hematol. 2008;87(9):735–40.
7. Gagne G, et al. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet. 2007;71(1):46–58.
8. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol. 1999;94(6):1593–600.
9. Bacon BR, et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med. 1999;130(12):953–62.
10. Olynyk JK, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341(10):718–24.
11. Allen KJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221–30.
12. Mclaren CE, et al. Prevalence of heterozygotes for hemochromatosis in the white-population of the United-States. Blood. 1995;86(5):2021–7.
13. Adams PC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–78.
14. Merryweather-Clarke A, et al. Geography of HFE C282Y and H63D mutations. Genet Test. 2000;4(3):183–98.
15. Biotechnology Australia, Genetics in Family Medicine: The Australian Handbook for General Practitioners: hereditary haemochromatosis, A.G.A.B. Australia, Editor. National Health and Medical Research Council: Canberra; 2007.
16. Barton J, Edwards CQ. Hemochromatosis: genetics, patholphysiology, diagnosis and treatment. Cambridge: Cambridge University Press; 2000.
17. Byrnes V, et al. The underdiagnosis of hereditary haemochromatosis: lack of presentation or penetration, expectations based on a study of relatives of symptomatic probands. Gastroenterology. 2000;118(4):A997.
18. Powell LW, Dixon JL, Hewett DG. Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis. Best Pract Res Clin Haematol. 2005;18(2):221–34.
19. McDonnell SM, et al. Screening for hemochromatosis in primary care settings. Ann Intern Med. 1998;129(11):962–70.
20. Adams PC, et al. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology. 1997;25(1):162–6.
21. Ajioka RS, Kushner JP. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood. 2003;101(9):3351–3 (discussion 3354–8).
22. Allen KJ, Warner B, Delatycki MB. Clinical haemochromatosis in HFE mutation carriers. Lancet. 2002;360(9330):412–3 (author reply 413–4).
23. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol. 1998;35(1):55–71.
24. Niederau C, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110(4):1107–19.
25. European Association for the Study of the L. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3–22.
26. Muncunill J, et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apher. 2002;17(2):88–92.
27. Adams P, et al. Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) study. Can J Gastroenterol. 2009;23(11):769–72.
28. Gasser B, et al. Hereditary hemochromatosis: presenting manifestations and diagnostic delay. Hémochromatose héréditaire: circonstances de découverte et délais diagnostiques. 2013.
29. Adams P, Brissot P, Powell L. EASL International Consensus Conference on Haemochromatosis—Part II. Expert document. J Hepatol. 2000;33(3):487–496.
30. Mundy L, Merlin T. Population genetic screening for haemochromatosis: identifying asymptomatic “at risk” homozygous individuals. Horizon scanning prioritising summary—volume 1. Adelaide Health Technology Assessment (AHTA); 2003.
31. Allen KJ. Population genetic screening for hereditary haemochromatosis: are we a step closer? Med J Aust. 2008;189(6):300–1.
32. Asberg A, et al. Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol. 2002;37(10):1212–9.
33. Barton JC, Acton RT. Population screening for hemochromatosis: has the time finally come? Curr Gastroenterol Rep. 2000;2(1):18–26.
34. Delatycki MB, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet. 2005;366(9482):314–6.
35. Gertig DM, Hopper JL, Allen KJ. Population genetic screening for hereditary haemochromatosis. Med J Aust. 2003;179(10):517–8.
36. Niederau C, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med. 1998;128(5):337–45.
37. Phatak PD, et al. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994;154(7):769–76.
38. Powell LW, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166(3):294–301.
39. Patch C, Roderick P, Rosenberg W. Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis. J Hepatol. 2005;43(1):149–55.
40. Delatycki MB, et al. ironXS: high-school screening for hereditary haemochromatosis is acceptable and feasible. Eur J Hum Genet. 2012;20(5):505–9.
41. Nisselle AE, et al. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis. Clin Genet. 2004;65(5):358–67.
42. Asberg A, et al. Screening for hemochromatosis: High prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36(10):1108–15.
43. Adams PC, et al. Screening for iron overload: Lessons from the HEmochromatosis and IRon Overload Screening (HEIRS) study. Can J Gastroenterol. 2009;23(11):769–72.
44. Bryant J, et al. Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation. Health Technol Assess. 2009;13(23):1–126.
45. Allen KJ, et al. Asymptomatic individuals at genetic risk of haemochromatosis take appropriate steps to prevent disease related to iron overload. Liver Int. 2008;28(3):363–9.
46. Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol. 2003;98(9):2072–7.
47. Nadakkavukaran IM, Gan EK, Olynyk JK. Screening for hereditary haemochromatosis. Pathology. 2012;44(2):148–52.
48. Wilson JMG, Junger G. Priciples and practice of screening for disease. Geneva: Switzerland; 1968.
49. Grosse SD, et al. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics. 2010;13(2):106–15.
50. Campbell and Cochrane Economics Methods GrouCampbell and Cochrane Economics Methods Group, How to add Health Economics to Cochrane Protocols. Available from http://www.c-cemg.org/. Accessed 10 Oct 2011.
51. Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, editors. Evidence-based decisions and economics: health care, social welfare, education and criminal justice. 2nd ed. Evidence-based medicine series. Chichester; Hoboken: Wiley-Blackwell/BMJ Books; 2010. p. 206.
52. Drummond MF, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
53. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–83.
54. Dissemination C.f.R.a. Systematic reviews: CRD’s guidance for undertaking reviews in health care. 3rd ed. York: Centre for Reviews and Dissemination; 2009.
55. Rombout-Sestrienkova E, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion. 2012;52(3):470–7.
56. Mariani R, et al. Erythrocytapheresis plus erythropoietin: An alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica. 2005;90(5):717–8.
57. Stefashyna O, et al. Pattern of care of blood donors with early-uncomplicated hereditary haemochromatosis in a Swiss blood donation centre. Vox Sang. 2014;106(2):111–7.
58. Dye DE, et al. The impact of single gene and chromosomal disorders on hospital admissions in an adult population. J Community Genet. 2011;2(2):81–90.
59. Gribble D, Chaffn DJ, Bryant BJ. Cost-effectiveness of fda variance for blood collection from individuals with hereditary hemochromatosis at a 398 bed hospital-based donor center. Transfusion. 2009;49:249A.
60. Cooper K, et al. A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations. QJM. 2008;101(8):631–41.
61. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterol Clin N Am. 1995;108:177–88.
62. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology (Baltimore, Md.). 1995;22(6):1720–27.
63. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994;154(7):769–76.
64. Schoffski O, Schmidtke J, Stuhrmann M. Cost-effectiveness of population-based genetic hemochromatosis screening. Community Genet. 2000;3:2–11.
65. Bassett ML, et al. Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers. J Hepatol. 1997;27(3):517–24.
66. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients—a cost-effectiveness analysis. Ann Intern Med. 2000;132(4):261–269.
67. Buffone GJ, Beck JR. Cost-effectiveness analysis for evaluation of screening programs—hereditary hemochromatosis. Clin Chem. 1994;40(8):1631–6.
68. Rogowski WH. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study. Med Decis Mak. 2009;29(2):224–38.
69. Stuhrmann M, Strassburg C, Schmidtke J. Genotype-based screening for hereditary haemochromatosis. I: technical performance, costs and clinical relevance of a German pilot study. Eur J Hum Genet. 2005;13(1):69–78.
70. Hickman PE, et al. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis. Gut. 2000;46(3):405–9.
71. Stave GM, et al. Evaluation of a workplace hemochromatosis screening program. Am J Prev Med. 1999;16(4):303–6.
72. Timms AE, et al. Genetic testing for haemochromatosis in patients with chondrocalcinosis. Ann Rheum Dis. 2002;61(8):745–7.
73. Vardarli I, et al. In hospitalized patients with diabetes mellitus screening for hereditary hemochromatosis by using transferrin saturation is cost effective. Diabetologia. 2009;52(S1):S398–9.
74. Smith BN, et al. Prevalence of hereditary hemochromatosis in a Massachusetts corporation: is celtic origin a risk factor? Hepatology. 1997;25(6):1439–46.
75. Barton JC, et al. Hemochromatosis detection in a health screening program at an Alabama forest products mill. J Occup Environ Med. 2002;44(8):745–51.
76. Adams PC. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis. Clin Genet. 1998;53(3):176–8.
77. Jacobs EM, et al. Impact of the introduction of a guideline on the targeted detection of hereditary haemochromatosis. Neth J Med. 2005;63(6):205–14.
78. Bhavnani M, et al. Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase. Gut. 2000;46(5):707–10.
79. Baer DM, et al. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med. 1995;98(5):464–8.
80. Adams PC, et al. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology. 2000;31(5):1160–4.
81. Balan V, et al. Screening for hemochromatosis—a cost-effectiveness study based on 12,258 patients. Gastroenterology. 1994;107(2):453–9.
82. Adams PC, Kertesz AE. Human leukocyte antigen typing of siblings in hereditary hemochromatosis: a cost approach. Hepatology. 1992;15(2):263–8.
83. Beutler E, Gelbart T. Large-scale screening for HFE mutations: methodology and cost. Genet Test. 2000;4(2):131–42.
84. Ropert-Bouchet M, Fajardy I, Michel H. Hereditary hemochromatosis HFE: regulatory and economic aspects of diagnosis and medical management. Ann Biol Clin (Paris). 2012;70(4):405–11.
85. Lederle FA. Screening for hemochromatosis? J Gen Intern Med. 1989;4(1):61–3.
86. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology. 1995;22(6):1720–7.
87. Schoffski O, Schmidtke J, Stuhrmann M. Cost-effectiveness of population-based genetic hemochromatosis screening. Community Genet. 2000;3(1):2–11.
88. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients: a cost-effectiveness analysis. Ann Intern Med. 2000;132(4):261–9.
89. Delaveyne R, Préaubert N, Barré S. Clinical and economic assessment of screening for HFE1 haemochromatosis in 2004. L’Agence Nationale d’Accreditation d’Evaluation en Sante (ANAES) Paris; 2004.
90. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0, J.P.T. Higgins, Green S, editors. The Cochrane Collaboration; 2011.
91. Popay J, et al. Guidance on the conduct of narrative synthesis in systematic reviews. UK: ESRC Methods Programme; 2006.
92. Balan V, et al. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology. 1994;107(2):453–9.
93. Patch C, Roderick P, Rosenberg W. Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: assessment of anxiety, depression, and perception of health. Genet Med. 2005;7(8):550–6.
94. Beutler E, et al. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133(5):329–37.
95. Asberg A, et al. Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol. 2002;37(10):1212–9.
96. Uhlig T, et al. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34(6):1241–7.
97. Dan AA, et al. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl. 2008;14(3):321–6.
98. Fryback DG, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care. 2007;45(12):1162–70.
99. Adams PC, Speechley M. The effect of arthritis on the quality of life in hereditary hemochromatosis. J Rheumatol. 1996;23(4):707–10.
100. Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care. 2006;22(3):327–37.
101. Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116(3):317–25.
102. Sahinbegovic E, et al. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum. 2010;62(12):3792–8.
103. Barton JC, et al. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening. Am J Hematol. 2008;83(2):126–32.
104. McLaren GD, et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol. 2008;22(11):923–30.
105. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Mak. 2008;28(4):582–92.
106. Lung TW, et al. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res. 2011;20(10):1669–78.
107. Holland R, et al. Patients’ self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J Card Fail. 2010;16(2):150–6.